301 related articles for article (PubMed ID: 12375050)
1. The Das-1 immunostain is useful for discriminating metastatic colon adenocarcinoma from cholangiocarcinoma and hepatocellular carcinoma.
Zimmerman RL; Das KM; Fogt F; Burke M; Murakata LA
Oncol Rep; 2002; 9(6):1369-72. PubMed ID: 12375050
[TBL] [Abstract][Full Text] [Related]
2. The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma.
Shiran MS; Isa MR; Sherina MS; Rampal L; Hairuszah I; Sabariah AR
Malays J Pathol; 2006 Dec; 28(2):87-92. PubMed ID: 18376797
[TBL] [Abstract][Full Text] [Related]
3. The clinical utility of the Das-1 monoclonal antibody in identifying adenocarcinoma of the colon metastatic to the liver in fine-needle aspiration tissue.
Zimmerman RL; Das KM; Burke MA; Young NA; Solomides CC; Bibbo M
Cancer; 2002 Dec; 96(6):370-3. PubMed ID: 12478685
[TBL] [Abstract][Full Text] [Related]
4. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma.
Ushiku T; Shinozaki A; Shibahara J; Iwasaki Y; Tateishi Y; Funata N; Fukayama M
Am J Surg Pathol; 2010 Apr; 34(4):533-40. PubMed ID: 20182341
[TBL] [Abstract][Full Text] [Related]
5. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
Abe N; Watanabe T; Izumisato Y; Suzuki Y; Masaki T; Mori T; Sugiyama M; Fusco A; Atomi Y
J Gastroenterol; 2003; 38(12):1144-9. PubMed ID: 14714251
[TBL] [Abstract][Full Text] [Related]
6. Distinction between hepatocellular carcinoma, cholangiocarcinoma, and metastatic carcinoma based on immunohistochemical staining for carcinoembryonic antigen and for cytokeratin 19 on paraffin sections.
Balaton AJ; Nehama-Sibony M; Gotheil C; Callard P; Baviera EE
J Pathol; 1988 Dec; 156(4):305-10. PubMed ID: 2465399
[TBL] [Abstract][Full Text] [Related]
7. [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy].
Tischoff I; Tannapfel A
Zentralbl Chir; 2007 Aug; 132(4):300-5. PubMed ID: 17724632
[TBL] [Abstract][Full Text] [Related]
8. Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver.
Lei JY; Bourne PA; diSant'Agnese PA; Huang J
Am J Clin Pathol; 2006 Apr; 125(4):519-25. PubMed ID: 16627262
[TBL] [Abstract][Full Text] [Related]
9. The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver.
Maeda T; Kajiyama K; Adachi E; Takenaka K; Sugimachi K; Tsuneyoshi M
Mod Pathol; 1996 Sep; 9(9):901-9. PubMed ID: 8878022
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.
Zimmerman RL; Fogt F; Burke M; Murakata LA
Oncol Rep; 2002; 9(4):689-92. PubMed ID: 12066193
[TBL] [Abstract][Full Text] [Related]
11. A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma.
Wakasa T; Wakasa K; Shutou T; Hai S; Kubo S; Hirohashi K; Umeshita K; Monden M
Hepatogastroenterology; 2007 Mar; 54(74):508-13. PubMed ID: 17523309
[TBL] [Abstract][Full Text] [Related]
12. [The value of CA19-9 in diagnosing hepatocellular carcinoma and intrahepatic cholangiocarcinoma].
Chen Y; Wang ZM; Ren ZG; Le F; Zhang BH; Xia JL; Ye SL; Tang ZY
Zhonghua Gan Zang Bing Za Zhi; 2006 Apr; 14(4):299-300. PubMed ID: 16635306
[No Abstract] [Full Text] [Related]
13. Histologic differentiation of hepatocellular carcinoma from adenocarcinoma by a simple panel: evaluation of the pitfalls.
Geramizadeh B; Boub R; Rahsaz M
Indian J Pathol Microbiol; 2007 Jul; 50(3):507-10. PubMed ID: 17883119
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma].
Dong H; Cong WL; Zhu ZZ; Wang B; Xian ZH; Yu H
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):702-5. PubMed ID: 19173916
[TBL] [Abstract][Full Text] [Related]
15. The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma.
Aishima S; Asayama Y; Taguchi K; Sugimachi K; Shirabe K; Shimada M; Sugimachi K; Tsuneyoshi M
Mod Pathol; 2002 Nov; 15(11):1181-90. PubMed ID: 12429797
[TBL] [Abstract][Full Text] [Related]
16. Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma.
Röcken C; Licht J; Roessner A; Carl-McGrath S
J Clin Pathol; 2005 Oct; 58(10):1069-75. PubMed ID: 16189153
[TBL] [Abstract][Full Text] [Related]
17. [Anatomo-pathologic diagnostic interpretation of nodular hepatic lesions].
Chiaramondia M; Ceppa P; Baccini P; Badini A; Castellaneta A
Pathologica; 1993; 85(1100):687-99. PubMed ID: 8170717
[TBL] [Abstract][Full Text] [Related]
18. Management of combined hepatocellular and cholangiocarcinoma.
Kassahun WT; Hauss J
Int J Clin Pract; 2008 Aug; 62(8):1271-8. PubMed ID: 18284443
[TBL] [Abstract][Full Text] [Related]
19. A resected case of a small hepatocellular carcinoma developing within the bile duct.
Yasui O; Sato T; Andoh H; Kurokawa T; Watanabe D; Sageshima M; Nanjo H
J Hepatobiliary Pancreat Surg; 2004; 11(3):193-6. PubMed ID: 15235893
[TBL] [Abstract][Full Text] [Related]
20. Topographical immunohistochemical expression of bcl-2 protein in human liver lesions.
Skopelitou A; Hadjiyannakis M; Alexopoulou V; Krikoni O; Kamina S; Agnantis N
Anticancer Res; 1996; 16(2):975-8. PubMed ID: 8687162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
